The effects on glucose metabolism by the beta-blocker atenolol and the angiotensin-converting enzyme (ACE)-inhibitor trandolapril were investigated in a randomised double-blind parallel group study of patients with primary hypertension. Twenty-six patients were treated with 50-100 mg atenolol and 27 patients with 2-4 mg trandolapril o.d. Intravenous glucose tolerance tests, euglycaemic hyperinsulinaemic clamps and serum lipid measurements were performed after 8 and 48 weeks of active treatment. After 48 weeks insulin sensitivity was reduced by 23% by atenolol while it remained unchanged during trandolapril treatment (؉0.5%, P ‫؍‬ 0.0010 for difference between treatments, ANCOVA). The effect on triglycerides (؉22% vs ؊8.5%)
Introduction
It has been shown that antihypertensive treatment increases the risk for diabetes mellitus. 1, 2 One possible mediator of that effect may be the impaired insulin sensitivity associated with the use of betablockers and diuretics, the dominating drug classes in these epidemiological studies. [3] [4] [5] Furthermore, recently a randomised intervention study showed that treatment based on the angiotensin-converting enzyme (ACE)-inhibitor, captopril, was associated with a lower incidence of diabetes than conventional antihypertensive treatment. 6 Patients with primary hypertension are insulin resistant. 7, 8 Elevated plasma insulin levels, an indirect marker of insulin resistance, are associated with increased risk of coronary heart disease. [9] [10] [11] [12] Therefore, metabolic factors may contribute to the excess risk for coronary heart disease associated with even well-controlled treated hypertension. 13, 14 However, there has been some uncertainty as to whether the metabolic effects of antihypertensive drugs persist during continuing treatment since most metabolic studies have had a duration of 6 months or less. Therefore, we wanted to study the metabolic effects of the ACE inhibitor trandolapril and the beta-blocker atenolol in a randomised double-blind parallel group trial with endpoint assessment after 8 and у48 weeks to see whether the effects differed between the long and short term.
Patients and methods

Patients and protocol
Patients were recruited through advertisements in the local newspapers. At the initial screening visit inclusion and exclusion criteria (Table 1) were assessed, informed consent was obtained, and any ongoing antihypertensive medication was stopped. After that, blood pressure (BP) was monitored at regular visits at the clinic. When the diastolic BP (DBP) reached 95 mm Hg single-blind placebo administration was initiated. As soon as a patient had met the BP criterion for inclusion in the active phase, randomisation was performed and baseline investigations were carried out. Intravenous glucose tolerance tests and the euglycaemic, hyperinsulinaemic clamps were performed on separate days, so that the investigations were performed during a period of 4 -8 days. All metabolic investigations were performed in the morning after an overnight fast and before . At each of these visits adverse events and concomitant medication were monitored by a trained nurse. After 4 weeks, the dose was doubled if the DBP was Ͼ90 mm Hg. Eight weeks into the active phase, investigations were repeated and patients were dropped out if their DBP was Ͼ95 mm Hg on two consecutive measurements. A third assessment of end-points was performed after 48 weeks of active treatment.
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Office blood pressure
Supine BP and heart rate were measured in triplicate by trained personnel. Cuff sizes of 12 × 45 or 15 × 45 cm were used depending on the arm circumference. The three measurements on each occasion were averaged and the mean value of the DBP was the basis for treatment decisions. Normalisation was defined as a DBP р90 mm Hg at the time-point at which efficacy was assessed (8 or 48 weeks). In addition, responders were defined as patients having normalised or reduced their DBP у10 mm Hg during the observation period. 
Insulin sensitivity measurements
Whole body sensitivity to insulin was measured by the euglycaemic hyperinsulinaemic clamp procedure according to DeFronzo et al, 15 with minor modifications. Insulin (Actrapid Human ® , Novo, Copenhagen, Denmark) was infused at a rate of 56 mU/(min/m 2 body surface area). The amount of glucose infused to maintain the target glucose level during the period of assumed steady-state was defined as glucose uptake (M; mg/kg/min). Adjustment for the steady-state insulin concentration defined the insulin sensitivity index (M/I; mg/min/kg/(mU/l). The intra-individual coefficient of variation for the insulin sensitivity index in our laboratory was 14%.
Intravenous glucose tolerance test (IVGTT)
Each patient's response to an intravenous glucose load was assessed by a 90-min intravenous glucose tolerance test. The glucose load was an intravenous injection within 1.5 min of 300 mg glucose per kg of body weight in a 50% glucose solution. The disappearance rate of glucose was expressed as a k value calculated from the formula k = ln2 × 100/t 1/2 where t 1/2 is the time required for the glucose concentration to be halved. Plasma glucose was measured by the glucose dehydrogenase method (Gluc-DH ® , Merck, Darmstadt, Germany). Insulin was assayed in EDTA plasma in duplicate using an enzymatic-immunological assay (Enzymmun®, Boehringer Mannhein, Germany) performed in a ES300 automatic analyser (Boehringer Mannheim). The mean fasting plasma glucose and insulin values were calculated from three blood samples drawn 5 min apart prior to the injection of glucose. Peak insulin response was defined as the mean of insulin values measured in the samples drawn at 4, 6, and 8 min and the insulin increment is reported as the difference between the peak and mean fasting value. Area under the incremental curve (AUC) for glucose and insulin was calculated by a trapezoid method.
Lipid and lipoprotein measurement
Cholesterol and triglyceride concentrations in serum were assayed by enzymatic techniques (Instrumentation Laboratories, Lexington, MA, USA) in a Monarch 2000 centrifugal analyzer. High-density lipoproteins (HDL) were separated by precipitation with magnesium cloride/phosphotungstate. Lowdensity lipoprotein (LDL) cholesterol was calculated using Friedewald's formula: LDL = serum cholesterol-HDL-(0.45 serum triglycerides).
Plasminogen activator inhibtor-1 (PAI-1) activity
PAI-1 activity was analysed in 18 atenolol treated and 20 trandolapril treated patients with a two-step indirect enzymatic assay (Spectrolyse ® /pL PAI kits, Biopool AB, Umeå, Sweden). The activity is given in U/mL, where one unit is the amount of PAI-1 that inhibits one international unit of single chain tissuetype plasminogen activator.
Clinical laboratory
All other blood and urinary analyses were performed at the Department of Clinical Chemistry, University Hospital, Uppsala, using routine laboratory methods.
Anthropometric measurements
Height was measured to the nearest whole centimetre and body weight was measured to the nearest 100 g. The body mass index (BMI) was calculated as the ratio of the weight in kg to the square of the height in meters.
Statistical analysis
The predetermined primary target variables were the differences in effect on glucose uptake and insulin sensitivity index between the two treatment modalities. Data processing was performed using the statistical program package SAS version 6.04 for personal computers. All tests used have been twosided. When necessary, variables were logarithmically tranformed to allow hypothesis testing using parametric tests. If this was not feasible, Wilcoxon's signed rank test or Mann-Whitney's U-test was used. Testing for differences between treatment groups and between treatments and placebo was performed according to the principle of intention-totreat using a model for analysis of covariance using factors for treatment and study period with adjustment for baseline values. Testing for baseline differences in nominal variables between groups was done using the 2 test or Fisher's exact test, as appropriate. Changes over time within each treatment group were calculated from the observed means. Statistical significance was accepted for P-values of Ͻ0.05 or a 95% confidence interval that excluded the value for no difference. If no mention of statistical significance is indicated in tables, figures or text, it means not significant by default.
Results
Patient flow and drop-outs
A total of 175 patients were recruited into the drugfree run-in period, and 53 were randomised and included in the intention-to-treat analysis. The overwhelming majority of drop-outs during the pre-randomisation phase were patients who did not reach inclusion BP when their habitual antihypertensive medication was discontinued. Twenty-six patients in the trandolapril group and 23 patients in the atenolol group experienced adverse events. The most common were headache (five out of 26 patients in the atenolol group, four out of 27 in the trandolapril group), cough (one out of 26 for atenolol, seven out of 27 for trandolapril), clinically relevant hyperlipidaemia (nine out of 26 for atenolol, two out of 27 for trandolapril). There were two discontinuations due to adverse events, one patient with depression and impotence in the atenolol group and one patient with intolerable cough in the trandolapril group.
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Baseline homogeneity
Baseline characteristics are reported in Table 2 . The two groups were similar with the exception of BP which was higher in the atenolol treated group.
Insulin sensitivity
Adjusted means for each treatment group and Pvalues with 95% confidence intervals for treatment differences are reported in Table 3 . The withingroup changes in selected variables are shown in Figure 1 . Atenolol reduced insulin sensitivity by 18% after 8 weeks and 23% after 48 weeks whereas trandolapril was neutral in this respect (−1.9% and +0.5% after 8 and 48 weeks, respectively). The differences in treatment effect were highly significant.
Glucose tolerance
There was no persistent effect on glucose tolerance by either treatment. At 8 weeks the trandolapril group had significantly higher k-values at the IVGTT (Table 3) , a result that seemed to be dependent on a transient increase (+12%) in the k-value by trandolapril. Both treatments had similar effects on serum potassium concentrations.
Lipid metabolism
The lipid changes followed the changes in insulin sensitivity. There was a significantly more favourable effect on triglycerides and HDL-cholesterol by trandolapril than atenolol at 8 weeks as well as at 48 weeks (Table 3 ). There was, however, a tendency towards an improvement in triglyceride levels with time in the atenolol group since 48-week values did not differ significantly from baseline (1.66 vs 1.36, P = 0.09).
Plasminogen activator inhibitor-1 (PAI-1) levels
In the atenolol group, PAI-1 levels increased by 27% after 48 weeks. During trandolapril treatment PAI-1 levels decreased by 6%. The difference between treatments was not significant (P = 0.067).
Blood pressure
Treatment effects on blood pressure are reported in Table 3 . Blood pressure was well controlled in both groups with a tendency towards a larger blood pressure reduction in the atenolol group. At 48 weeks the response rates were 67% and 88% for trandolapril and atenolol, respectively (P = 0.10) and the normalisation rates were 63% in the trandolapril group and 85% in the atenolol group (P = 0.12).
Body weight
Body weight was unchanged in the atenolol group after 8 weeks but had increased by 2.0 kg after 48 weeks. Trandolapril had no effect on body weight (−0.5 kg at 48 weeks, P = 0.19). Atenolol and trandolapril had significantly different effects on body weight after 48 weeks (P Ͻ 0.0002), but not after 8 weeks (P = 0.13).
Correlation analysis
There was no correlation between change in serum potassium and change in either glucose tolerance or insulin sensitivity either in the study as a whole or in either of the treatment groups. In the atenolol group, the low-dose group tended to decrease more in insulin sensitivity index than the high-dose group (−35% vs −12.5%, P = 0.053). In the trandolapril group the response was not different between doses (P = 0.76).
Discussion
This study confirms previous studies that have reported impaired insulin sensitivity during treatment with atenolol, 3, 4 and demonstrates that the response to the ACE inhibitor trandolapril is significantly more favourable in this respect. Importantly, the effects of the two drugs remained unchanged after 11 months treatment as compared to the 2-months data, indicating that the reduced insulin action during atenolol is not ameliorated after prolonged treatment. The difference in effect by the two drugs corresponded to roughly 25% of the baseline values of insulin sensitivity. A prolonged difference in insulin sensitivity of this magnitude for the duration of decades may have clinical consequences such as an increased risk of diabetes mellitus. An increased risk of diabetes associated with beta-blockade and diuretic treatment has indeed been demonstrated recently. 2 In the recently published CAPPP-study ACE-inhibitor based treatment reduced the incidence of diabetes as compared to conventional antihypertensive treatment. 6 It has been speculated that the difference in metabolic effects between beta-blockers and ACE-inhibitors is due to effects on potassium balance and the fact that potassium is not infused during hyperinsulinaemia. 16 In this study there was no relationship between the change in potassium and the change in insulin sensitivity or glucose tolerance during treatment. Furthermore, the two drugs induced almost identical increases in serum potassium, which makes it unlikely that the different metabolic effects of the two drugs were secondary to different effects on potassium homeostasis.
Body weight increased significantly in the atenolol-treated group but this slow increase in body weight developed mainly in the period between 8 and 48 weeks, whereas the insulin resistance was nearly completely developed already after 8 weeks' treatment. This sequence of events indicates that the difference in effect on insulin sensitivity between the two drugs was not exclusively mediated by changes in body weight. The impaired insulin sensitivity in the atenolol treated group was not reflected in impaired glucose tolerance, as represented by fasting glucose and glucose disappearance rate during the IVGTT. Lipid levels were affected in the typical pattern for beta-blockers by atenolol. This was reflected in the pattern of adverse event as nine
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reports of clinically relevant hyperlipidaemia in comparison to two reports in the trandolapril treated group. In contrast to the insulin sensitivity data there was a tendency towards normalisation of the triglyceride levels with sustained treatment. In a previous open long-term follow-up study we observed that the effects on insulin sensitivity as well as on lipids persisted over a period of 2-3 years. 17 It is therefore possible that the apparent amelioration of the hypertriglyceridaemia with time in the present study may be the result of random fluctuations.
Non-insulin-dependent diabetes as well as insulin resistance are associated with an increased cardiovascular risk. 2, [9] [10] [11] [12] The fast inhibitor of fibrinolysis, PAI-1, which is elevated in these conditions, has been suggested to play a role in this association. 18 Although no consistent change in PAI-1 levels have been reported in other studies, 19 we have previously found a 17% increase in PAI-1 levels during atenolol treatment which did not quite reach statistical significance. 20 The changes in PAI-1 levels in this study followed the pattern of changes in triglycerides and insulin sensitivity. This could be an indication that PAI-1 is mechanistically linked to the insulin sensitivity-metabolic complex.
Atenolol reduced BP better than trandolapril at the doses selected for this study, even if the difference was statistically significant only for DBP after 48 weeks. It is not likely that the difference in effects on insulin sensitivity was due to inappropriately high doses of atenolol, since, if anything, patients in the low-dose group experienced a larger decrease in insulin sensitivity than the high-dose group.
Are metabolic effects induced by antihypertensive treatment of any consequence for the prognosis of hypertensive patients? The data from a recently published randomised intervention study in hypertensives 6 supports the hypothesis that the differences in metabolic profiles between ACE-inhibitors and conventional antihypertensive treatment translates into a difference in diabetes incidence. On the other hand, one study has failed to show an increased risk of coronary heart disease associated with diabetes diagnosed during follow-up of treated hypertensive patients. 21 The confidence interval for the risk estimate was very wide in that study, however, and included a relative risk of up to 6. The same group reported that the on-treatment level of serum cholesterol, but not BP, was an independent determinant of coronary heart disease in a long-term follow-up of treated hypertensive patients. 14 Concerning patients that are already diabetic, the data from the UKPDS antihypertensive treatment study in type 2 diabetics indicates that BP reduction seems at least as important as tight metabolic control for the reduction of cardiovascular events. 22, 23 In the same prospective study, randomised treatment with atenolol was associated with higher levels of glycated haemoglobin, a higher frequency of additional glucose lowering treatment and a greater weight gain but this did not result in poorer outcome in terms of clinical events 24 and there was no recommendation for the use of one treatment in preference to the other. Taken together, these data suggests that in hypertensive patients metabolic factors may or may not be important, whereas in diabetic patients the achieved BP levels may be most important for the clinical outcome of patients treated with anthypertensive drugs.
In summary, trandolapril compared favourably to atenolol in its effect on insulin sensitivity and lipid profile while there was no sustained difference in effect on glucose tolerance. The difference in effect was large enough to be in line with the difference in risk for diabetes in treated hypertensive patients and the difference in metabolic control in type 2 diabetes when ACE inhibitors and beta-blockers are compared.
